USPTO serial 76496366
AVONTEC
Reviewed by CopyMark Law Group
Status 603
- Filing date
- Status date
- Registration date
- —
- Examiner
- STOIDES, KATHERINE
- Law office
- TMEG LAW OFFICE 101 - EXAMINING ATTORNEY ASSIGNED
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with AVONTEC?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Gottingen, DE
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Beate Boudro, J.D.
L ALISON DAVIS FULBRIGHT & JAWORSKI LLP600 CONGRESS AVE STE 2400AUSTIN, TX 78701UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical preparations, namely buffer, lyophilisates, dispersion solutions, emulsions, suspensions, liposomes, additives, polypeptides for scientific purposes; chemical preparations for the investigation and characterization of diseases, namely, of cardiovascular diseases, inflammations, autoimmune diseases, rheumatoid arthritis, psoriasis, gastro-intestinal diseases, Crohn's diseases, ulcerativ colitis, diabetes, nephropathy, retinopathy, vasculopathy, vasculitis, transplant rejections, graft versus host and host versus graft diseases, ischaemia, hypertension, aneurysms, renal failure, pulmonary diseases, infectious and post-infectious diseases, immunological disorders, allergic reactions, coronary heart diseases, restenosis, metabolic disorders, malignancies, except neurological disorders; nucleic acids for scientific purposes | ACTIVE | — |
| 005 | Medicaments for the treatment of cardiovascular diseases, inflammations, autoimmune diseases, rheumatoid arthritis, psoriasis, gastro-intestinal diseases, Crohn's diseases, ulcerativ colitis, diabetes, nephropathy, retinopathy, vasculopathy, vasculitis, transplant rejections, graft versus host and host versus graft diseases, ischaemia, hypertension, aneurysms, renal failure, pulmonary diseases, infectious and post-infectious diseases, immunological disorders, allergic reactions, coronary heart diseases, restenosis, metabolic disorders, malignancies, except neurological disorders; pharmaceutical and veterinary preparations for the control of the expression of genes relevant to said diseases; preparations for diagnosis and analysis of cardiovascular diseases, inflammations, autoimmune diseases, rheumatoid arthritis, psoriasis, gastro-intestinal diseases, Crohn's diseases, ulcerativ colitis, diabetes, nephropathy, retinopathy, vasculopathy, vasculitis, transplant rejections, graft versus host and host versus graft diseases, ischaemia, hypertension, aneurysms, renal failure, pulmonary diseases, infectious and post-infectious diseases, immunological disorders, allergic reactions, coronary heart diseases, restenosis, metabolic disorders, malignancies, except neurological disorders; nucleic acids for medical, analytical and diagnostic purposes | ACTIVE | — |
| 035 | Arranging and conducting business conferences | ACTIVE | — |
| 041 | Educational services, namely offering seminars, workshops and symposiums in the fields of molecular biology, biotechnology, genetics, medicine and pharmacology; arranging educational conferences, and providing facilities for educational conventions | ACTIVE | — |
| 042 | Scientific and industrial research and consulting, particularly in the fields of molecular biology, biotechnology, genetics, medicine and pharmacology; identification of target structures for the development of medicaments, particularly polypeptides and nucleic acids; research and development of new technologies and pharmaceutical products for others, particularly for the control of the expression of genes relevant to diseases; product and technology research and development for others, namely, development of processes and products for scientific and industrial research, particularly in the fields of molecular biology, biotechnology, genetics, medicine and pharmacology; product development in the field of nucleic acids | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 23, 2005 | EXPT | EXPARTE APPEAL TERMINATED | — |
| May 23, 2005 | MAB3 | ABANDONMENT NOTICE MAILED - AFTER EX PARTE APPEAL | — |
| May 13, 2005 | ABN3 | ABANDONMENT - AFTER EX PARTE APPEAL | — |
| May 13, 2005 | EXFB | EXPARTE APPEAL DISMISSED - FAILURE TO FILE BRIEF | — |
| Jan 10, 2005 | GECD | ACTION DENYING REQ FOR RECON E-MAILED | — |
| Jan 10, 2005 | CNCF | ACTION CONTINUING FINAL - COMPLETED | — |
| Oct 14, 2004 | EXPI | EX PARTE APPEAL-INSTITUTED | — |
| Oct 14, 2004 | JURT | JURISDICTION RESTORED TO EXAMINING ATTORNEY | — |
| Oct 13, 2004 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| Oct 12, 2004 | EXAF | EXPARTE APPEAL RECEIVED AT TTAB | — |
| Sep 27, 2004 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 27, 2004 | PAPER RECEIVED | — | |
| May 10, 2004 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 22, 2004 | CNFR | FINAL REFUSAL MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Mar 5, 2004 | UNPR | UNRESPONSIVE/DUPLICATE PAPER RECEIVED | — |
| Mar 5, 2004 | FAXX | FAX RECEIVED | — |
| Feb 23, 2004 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 23, 2004 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 25, 2003 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 25, 2003 | DOCK | ASSIGNED TO EXAMINER | — |